German Patients Face 50% Copay Hike as Berlin Rushes to Plug €18.8 Billion Health Insurance Gap

The German government’s newly approved austerity package for the statutory health insurance system (GKV) aims to keep contribution rates stable through 2027 and 2028, but the price tag falls squarely on patients, drugmakers, and family policy. The GKV-Spitzenverband, the umbrella body for the country’s public insurers, has called the measures a “solid foundation” — though industry representatives warn there is zero room for weakening them.

A Deficit That Demands Exact Offsets

The arithmetic is stark. A financing gap of €18.8 billion is projected for 2027, and the package is designed to close it precisely. For 2028, a deficit of €25 billion is matched against planned relief of €25.3 billion. But the outlook beyond that remains precarious. For 2029 and 2030, relief measures worth over €30 billion are planned — yet these are unlikely to cover the deficits expected in those years.

The political target is an average add-on premium (Zusatzbeitrag) of 2.9 percent. Currently, it sits at 3.1 percent. Experts warn that if the savings targets are missed, the add-on rate could climb to as high as 3.5 percent in 2027.

Patients Shoulder 13 Percent of the Savings

From 2027, insured members will feel the pinch directly. Their share of the total savings amounts to 13 percent. The most significant changes include:

• Copayments rise by 50 percent: The minimum copay jumps to €7.50, the maximum to €15.
• Benefits slashed: Cannabis flower, homeopathy, and anthroposophic medicine are removed from the covered services list. Fixed subsidies for dental prosthetics drop by 10 percent.
• Family insurance surcharge: Spouses covered free of charge under family insurance will face a 2.5 percentage-point surcharge. Exceptions apply for parents raising children under 12 or those caring for dependents.

Starting in 2028, partial incapacity for work will be introduced, with sick pay paid in 25, 50, and 75 percent increments. Skin cancer screening will shift to a risk-based model.

Pharma Industry Squeezed as Investment Freezes

The package also reins in spending on hospitals, doctors’ offices, and pharmacies. Fees and clinic payments will be curbed but not cut. The most contentious measure: the manufacturer discount on patented drugs jumps from 7 percent to 15.5 percent. Industry groups warn of additional costs totaling roughly €4.5 billion by 2030.

Reactions were swift. In June 2026, Boehringer Ingelheim and Eli Lilly halted investments at their German sites. Experts caution that every euro in manufacturer discounts disproportionately reduces domestic value creation. Supply security remains a concern — Germany sources about 76 percent of its antibiotics from China.

Information Duty Scrapped, Consumer Groups Cry Foul

A controversial element of the reform eliminates the separate obligation for health insurers to notify members by letter about add-on premium increases and their special termination rights. The GKV-Spitzenverband expects administrative savings of around €100 million from this change.

Consumer advocates and opposition politicians condemn the move as a rollback of patient rights. One financial expert advises policyholders to regularly check their pay slips going forward. A SPD health politician has already called for new regulations on consumer information.

The pressure is already tangible: IKK Classic is raising its add-on premium from 3.4 percent to 3.85 percent effective August 1, 2026. Meanwhile, CDU leader Friedrich Merz defends plans for stricter rules on sick notes — including the possible abolition of telephone-based medical certificates. According to DAK analyses, the sickness rate for the first half of 2026 stood at 5.3 percent.

en | boerse | 69831954 |